REVIEW OF THE EFFECTIVENESS OF PALONOSETRON IN PREVENTION OF NAUSEAS AND VOMITS INDUCED FOR MELPHALNAN IN AUTOLOGUS TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS.
(Abstract release date: 05/19/16)
EHA Library. Saenz Fernandez C. 06/09/16; 135071; PB2171
Mrs. Cecilia Saenz Fernandez
Contributions
Contributions
Abstract
Abstract: PB2171
Type: Publication Only
Background
Prevention of nauseas and vomits induced for melphalan in autologus transplant of hematopoietic progenitor cells is an important issue. There is not an standar of care until now. In our work we review the effectiveness of Palonosetron for these patients.
Aims
Objective: assess the effectiveness and security of Palonosetron in the prevention of nauseas and vomits induced for melphalan at high dose (200mg/m2) in autologus transplant of hematopoietic progenitor cells
Methods
Material and methods: Observational study, descriptive and retrospective in which have been included patients older than 18 year old diagnosed of multiple myeloma and with autologus transplant of hematopoietic progenitor cells during the period March 2009-February 2014 which received Melphalan 200mg/m2 in day -4. For prevention of nauseas and vomits a dose of Palonosetron 250mcg was administer intravenous half an hour before the infusion of Mephalan was started. The identification of the subjects was done through the computer program of prescription, validation and preparation of cytostatic mixtures Oncofarm®. To assess the effectiveness a survey was used where patients had reflected nauseas and vomits during the four days after the administration of Mephalan and the notes of nursing and medical staff on the medical records. The variables used were, age, sex, toxic habits (tobacco, alcohol), scale of basal activity ECOG, digestive disease, regular medication, previous chemotherapy and anticipatory nauseas and vomits
Results
Results: 31 patients were included, 20 women (64.5%) and 11 men, mean age 59.4 years old. The 77.4% were not smokers and the 80.6% declared drink less than 30 grams of alcohol per week. At the moment of the transplant one patient had ECOG 1, and all the other patients ECOG 0. Nine patients (29%) were suffering some sort of digestive disease (Dyspepsia, peptic ulcer, hiatus hernia, gastroesophageal reflux disease or obstruction). The 71% (n=22) was been treated with opioids, antacids and/or benzodiazepines. The schemes of chemotherapy previous given were Bortezomid + Dexamethasone (n=24), Bortezomid +Thalidomide + Dexamethasone (n=5), Bortezomid + Dexamethasone + Cyclophosphamide (n=2), lenalidomide (n=3) and Vincristine + Doxorubicin + Dexamethasone (n=1). The 12.9% of the patients had nauseas or vomits in the last cycles. At the moment of the admission for the transplant only two patients had anticipatory nauseas. In the first 24 hours after mephalnan infusion and palonosetron administration 54.8% (n=17) suffered an episode of nauseas ( eight patients grade 1, eight grade 2, and one grade 3), and only nine had vomits (seven grade 1, one grade 2 and one grade 3). Between the next 24-96 hours 19 patients (61.3%) had nauseas (14 grade 1, two grade 2 and three grade 3), and 12 patients (38.7%) vomits (nine grade! and three grade 2). As rescue medication levomepromazine was used in the 35.5%. all the others were treated with metoclopramide, dexamethasone, domperidone and /or benzodiazepines.The only adverse effect documented after Palonosetron administration was constipation (n=2, 6.4%).
Conclusion
Conclusions: We can confirm the effectiveness and security of palonosetron in the prevention of nauseas and vomits induced for high dose of Mephalan. The results are similar to those reported in the available bibliography
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Melphalan, Prophylaxis
Type: Publication Only
Background
Prevention of nauseas and vomits induced for melphalan in autologus transplant of hematopoietic progenitor cells is an important issue. There is not an standar of care until now. In our work we review the effectiveness of Palonosetron for these patients.
Aims
Objective: assess the effectiveness and security of Palonosetron in the prevention of nauseas and vomits induced for melphalan at high dose (200mg/m2) in autologus transplant of hematopoietic progenitor cells
Methods
Material and methods: Observational study, descriptive and retrospective in which have been included patients older than 18 year old diagnosed of multiple myeloma and with autologus transplant of hematopoietic progenitor cells during the period March 2009-February 2014 which received Melphalan 200mg/m2 in day -4. For prevention of nauseas and vomits a dose of Palonosetron 250mcg was administer intravenous half an hour before the infusion of Mephalan was started. The identification of the subjects was done through the computer program of prescription, validation and preparation of cytostatic mixtures Oncofarm®. To assess the effectiveness a survey was used where patients had reflected nauseas and vomits during the four days after the administration of Mephalan and the notes of nursing and medical staff on the medical records. The variables used were, age, sex, toxic habits (tobacco, alcohol), scale of basal activity ECOG, digestive disease, regular medication, previous chemotherapy and anticipatory nauseas and vomits
Results
Results: 31 patients were included, 20 women (64.5%) and 11 men, mean age 59.4 years old. The 77.4% were not smokers and the 80.6% declared drink less than 30 grams of alcohol per week. At the moment of the transplant one patient had ECOG 1, and all the other patients ECOG 0. Nine patients (29%) were suffering some sort of digestive disease (Dyspepsia, peptic ulcer, hiatus hernia, gastroesophageal reflux disease or obstruction). The 71% (n=22) was been treated with opioids, antacids and/or benzodiazepines. The schemes of chemotherapy previous given were Bortezomid + Dexamethasone (n=24), Bortezomid +Thalidomide + Dexamethasone (n=5), Bortezomid + Dexamethasone + Cyclophosphamide (n=2), lenalidomide (n=3) and Vincristine + Doxorubicin + Dexamethasone (n=1). The 12.9% of the patients had nauseas or vomits in the last cycles. At the moment of the admission for the transplant only two patients had anticipatory nauseas. In the first 24 hours after mephalnan infusion and palonosetron administration 54.8% (n=17) suffered an episode of nauseas ( eight patients grade 1, eight grade 2, and one grade 3), and only nine had vomits (seven grade 1, one grade 2 and one grade 3). Between the next 24-96 hours 19 patients (61.3%) had nauseas (14 grade 1, two grade 2 and three grade 3), and 12 patients (38.7%) vomits (nine grade! and three grade 2). As rescue medication levomepromazine was used in the 35.5%. all the others were treated with metoclopramide, dexamethasone, domperidone and /or benzodiazepines.The only adverse effect documented after Palonosetron administration was constipation (n=2, 6.4%).
Conclusion
Conclusions: We can confirm the effectiveness and security of palonosetron in the prevention of nauseas and vomits induced for high dose of Mephalan. The results are similar to those reported in the available bibliography
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Melphalan, Prophylaxis
Abstract: PB2171
Type: Publication Only
Background
Prevention of nauseas and vomits induced for melphalan in autologus transplant of hematopoietic progenitor cells is an important issue. There is not an standar of care until now. In our work we review the effectiveness of Palonosetron for these patients.
Aims
Objective: assess the effectiveness and security of Palonosetron in the prevention of nauseas and vomits induced for melphalan at high dose (200mg/m2) in autologus transplant of hematopoietic progenitor cells
Methods
Material and methods: Observational study, descriptive and retrospective in which have been included patients older than 18 year old diagnosed of multiple myeloma and with autologus transplant of hematopoietic progenitor cells during the period March 2009-February 2014 which received Melphalan 200mg/m2 in day -4. For prevention of nauseas and vomits a dose of Palonosetron 250mcg was administer intravenous half an hour before the infusion of Mephalan was started. The identification of the subjects was done through the computer program of prescription, validation and preparation of cytostatic mixtures Oncofarm®. To assess the effectiveness a survey was used where patients had reflected nauseas and vomits during the four days after the administration of Mephalan and the notes of nursing and medical staff on the medical records. The variables used were, age, sex, toxic habits (tobacco, alcohol), scale of basal activity ECOG, digestive disease, regular medication, previous chemotherapy and anticipatory nauseas and vomits
Results
Results: 31 patients were included, 20 women (64.5%) and 11 men, mean age 59.4 years old. The 77.4% were not smokers and the 80.6% declared drink less than 30 grams of alcohol per week. At the moment of the transplant one patient had ECOG 1, and all the other patients ECOG 0. Nine patients (29%) were suffering some sort of digestive disease (Dyspepsia, peptic ulcer, hiatus hernia, gastroesophageal reflux disease or obstruction). The 71% (n=22) was been treated with opioids, antacids and/or benzodiazepines. The schemes of chemotherapy previous given were Bortezomid + Dexamethasone (n=24), Bortezomid +Thalidomide + Dexamethasone (n=5), Bortezomid + Dexamethasone + Cyclophosphamide (n=2), lenalidomide (n=3) and Vincristine + Doxorubicin + Dexamethasone (n=1). The 12.9% of the patients had nauseas or vomits in the last cycles. At the moment of the admission for the transplant only two patients had anticipatory nauseas. In the first 24 hours after mephalnan infusion and palonosetron administration 54.8% (n=17) suffered an episode of nauseas ( eight patients grade 1, eight grade 2, and one grade 3), and only nine had vomits (seven grade 1, one grade 2 and one grade 3). Between the next 24-96 hours 19 patients (61.3%) had nauseas (14 grade 1, two grade 2 and three grade 3), and 12 patients (38.7%) vomits (nine grade! and three grade 2). As rescue medication levomepromazine was used in the 35.5%. all the others were treated with metoclopramide, dexamethasone, domperidone and /or benzodiazepines.The only adverse effect documented after Palonosetron administration was constipation (n=2, 6.4%).
Conclusion
Conclusions: We can confirm the effectiveness and security of palonosetron in the prevention of nauseas and vomits induced for high dose of Mephalan. The results are similar to those reported in the available bibliography
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Melphalan, Prophylaxis
Type: Publication Only
Background
Prevention of nauseas and vomits induced for melphalan in autologus transplant of hematopoietic progenitor cells is an important issue. There is not an standar of care until now. In our work we review the effectiveness of Palonosetron for these patients.
Aims
Objective: assess the effectiveness and security of Palonosetron in the prevention of nauseas and vomits induced for melphalan at high dose (200mg/m2) in autologus transplant of hematopoietic progenitor cells
Methods
Material and methods: Observational study, descriptive and retrospective in which have been included patients older than 18 year old diagnosed of multiple myeloma and with autologus transplant of hematopoietic progenitor cells during the period March 2009-February 2014 which received Melphalan 200mg/m2 in day -4. For prevention of nauseas and vomits a dose of Palonosetron 250mcg was administer intravenous half an hour before the infusion of Mephalan was started. The identification of the subjects was done through the computer program of prescription, validation and preparation of cytostatic mixtures Oncofarm®. To assess the effectiveness a survey was used where patients had reflected nauseas and vomits during the four days after the administration of Mephalan and the notes of nursing and medical staff on the medical records. The variables used were, age, sex, toxic habits (tobacco, alcohol), scale of basal activity ECOG, digestive disease, regular medication, previous chemotherapy and anticipatory nauseas and vomits
Results
Results: 31 patients were included, 20 women (64.5%) and 11 men, mean age 59.4 years old. The 77.4% were not smokers and the 80.6% declared drink less than 30 grams of alcohol per week. At the moment of the transplant one patient had ECOG 1, and all the other patients ECOG 0. Nine patients (29%) were suffering some sort of digestive disease (Dyspepsia, peptic ulcer, hiatus hernia, gastroesophageal reflux disease or obstruction). The 71% (n=22) was been treated with opioids, antacids and/or benzodiazepines. The schemes of chemotherapy previous given were Bortezomid + Dexamethasone (n=24), Bortezomid +Thalidomide + Dexamethasone (n=5), Bortezomid + Dexamethasone + Cyclophosphamide (n=2), lenalidomide (n=3) and Vincristine + Doxorubicin + Dexamethasone (n=1). The 12.9% of the patients had nauseas or vomits in the last cycles. At the moment of the admission for the transplant only two patients had anticipatory nauseas. In the first 24 hours after mephalnan infusion and palonosetron administration 54.8% (n=17) suffered an episode of nauseas ( eight patients grade 1, eight grade 2, and one grade 3), and only nine had vomits (seven grade 1, one grade 2 and one grade 3). Between the next 24-96 hours 19 patients (61.3%) had nauseas (14 grade 1, two grade 2 and three grade 3), and 12 patients (38.7%) vomits (nine grade! and three grade 2). As rescue medication levomepromazine was used in the 35.5%. all the others were treated with metoclopramide, dexamethasone, domperidone and /or benzodiazepines.The only adverse effect documented after Palonosetron administration was constipation (n=2, 6.4%).
Conclusion
Conclusions: We can confirm the effectiveness and security of palonosetron in the prevention of nauseas and vomits induced for high dose of Mephalan. The results are similar to those reported in the available bibliography
Session topic: E-poster
Keyword(s): Autologous bone marrow transplant, Melphalan, Prophylaxis
{{ help_message }}
{{filter}}